NVS Novartis AG

   By Mauro Orru 
 

Novartis AG said Saturday that its Phase 3 Combi-i study for investigational monoclonal antibody spartalizumab in combination with Tafinlar and Mekinist in advanced melanoma didn't meet its primary endpoint.

The Swiss pharmaceutical company said it would continue to review the data gathered despite the outcome, investigating the immunotherapy with other anti-cancer agents.

"While the Combi-i trial did not reach its primary endpoint, the study's findings give us valuable insights into the role the investigational immunotherapy spartalizumab may play in future cancer therapy combinations," Novartis Chief Medical Officer John Tsai said.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

August 24, 2020 01:36 ET (05:36 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.